Neutral
●
PRNewsWire
●
6 months ago
Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More Likely NEW YORK, March 25, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) lost more than 60% of its value after the Company's Phase 3 PROSERA trial of seralutinib missed its primary endpoint. In May 2025, CEO Faheem Hasnain told investors on the Q1 2025 earnings...